Seong-Rim Kim

发表

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

T. Nielsen, S. Loi, C. Denkert, 2017, Seminars in cancer biology.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe

Carsten Denkert, Fred Hirsch, Benjamin Solomon, 2017, Advances in anatomic pathology.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28.

T. Julian, S. Paik, G. Tang, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical significance of pmTOR expression in endometrioid endometrial carcinoma.

Seong-Rim Kim, Jeong-Won Lee, Tae-Joong Kim, 2010, European journal of obstetrics, gynecology, and reproductive biology.

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

S. Paik, J. Costantino, C. Geyer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.

N. Petrelli, S. Paik, N. Wolmark, 2013, Journal of the National Cancer Institute.

Genomics of adjuvant therapy for breast cancer.

S. Paik, Seong-Rim Kim, 2011, Cancer journal.

Abstract 2837: A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B-31 for HER2+ breast cancer

J. Costantino, C. Geyer, D. Wickerham, 2015 .

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Jong-Hyeon Jeong, Hanna Bandos, Debora Fumagalli, 2013, Journal of the National Cancer Institute.

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Clare C. Yu, M. N. Vidya, 2021, npj Breast Cancer.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma

Seong-Rim Kim, Jeong-Won Lee, Y. Lee, 2011, Journal of Cancer Research and Clinical Oncology.

Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.

N. Petrelli, S. Paik, N. Wolmark, 2013, Journal of the National Cancer Institute.